Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pedaling through chemo: could exercise boost tumor blood flow?

NCT ID NCT07785882

Symptom relief Sponsor: Kira Bloomquist Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests whether doing light-to-moderate aerobic exercise during chemotherapy infusions is safe and practical for people with sarcoma (a type of cancer). Participants will exercise in 15-minute intervals during each infusion, and researchers will also check if exercise temporarily increases blood flow to tumors, which might help chemo work better. The study compares side effects and quality of life against historical data from similar patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moderate-intensity aerobic exercise performed during chemotherapy infusion
What this could lead to
If safe and feasible, this approach could become a standard way to improve quality of life and potentially enhance chemotherapy effectiveness by increasing tumor blood flow.
What could go wrong
This is a small early-stage trial with only 16 participants, so results may not apply broadly. Exercise during infusion could pose risks like cardiac strain or muscle damage, which the study will monitor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Initiating at least two series of chemotherapy for non-resected sarcoma at Clinic 6, Herlev Hospital, Denmark * Eastern Cooperative Oncology Group performance status of 0-2 * No mental or physical disabilities precluding exercise * Approval by the treating oncologist * Able to read Danish * Willing to sign informed consent Exclusion Criteria: * Home-based chemotherapy * Infusions lasting under one hour * Elevated risk for developing cardiac issues (left ventricular ejection fraction ≤50%) based on routine echocardiography

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Oncology, Herlev Hospital

    Herlev, Region Sjælland, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.